ArticlemAbs2026
Balancing the extremes for antibody developability: hydrophobic and electrostatic germline framework signatures for CDR-loop compensation.
Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Antibody therapeutics are a rapidly growing class of biopharmaceuticals, but concerns regarding potential developability issues persist. While complementarity-determining region (CDR) loops are imperative for antigen specificity and mutations are challenging, the framework regions can be exchanged to align with developability attributes such as aggregation, clearance, and viscosity, all governed by physicochemical characteristics. In this study, we systematically analyze the electrostatic and hydrophobic surface properties of germline-encoded antibody frameworks to assess their role in modulating Fv developability. Using structure prediction and surface patch analysis, we identify differences between kappa and lambda light-chain frameworks, characterize outlier germlines with extreme surface properties, and demonstrate using hydrophobic interaction chromatography and a heparin column that framework selection can compensate for CDR loop physicochemical characteristics. Our findings reveal that rational framework selection can serve as a systematic tool for optimizing antibody developability. This study provides a toolbox for antibody design, enhancing therapeutic candidate selection by leveraging inherent germline properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.